NCT00106002

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

A Phase II Study of Alimta as First Line Chemotherapy for Advanced or Metastatic Breast Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purposes of this study are to determine whether pemetrexed can help patients with metastatic (cancer that has spread to other parts of the body) breast cancer, to determine any side effects that may be associated with the drug, to determine how much pemetrexed should be given to patients, and to collect DNA for future research regarding metastatic breast cancer. The collection of DNA is optional to the patient.

Conditions

• Breast Cancer
• Breast Neoplasms, Male
• Carcinoma, Ductal

Interventions

Type	Name	Description
DRUG	pemetrexed	600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression

Timeline

• Start date: 2005-04-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2005-03-21
• Last updated: 2009-06-01
• Results posted: 2009-06-01

Locations

1 site across 1 country: United States